Renal tubular dysgenesis and reversible hypocalvaria after intrauterine exposure to an angiotensin receptor blocker
Sir,
We report an infant with renal tubular dysgenesis (RTD) and hypocalvaria after intrauterine exposure to an angiotensin receptor blocker (ARB), in whom RTD is irreversible but hypocalvaria reversible.
A female infant was delivered at a gestational age of 35 weeks and 4 days, weighing 1,878 grams, to a gravid 4, para 4, 37-year-old woman, who received an ARB because of hypertension. The mother received olmesartan medoxomil (40 mg/day) during pregnancy. Ultrasound examination revealed oligohydramnios and intrauterine growth restriction. The infant developed anuria and respiratory distress, requiring mechanical ventilation. Serum creatinine was 3.36 mg/dL on Day 4. Serum concentrations of olmesartan medoxomil on Days 1 and 3 were 21.8 ng/mL and 14.7 ng/mL, respectively. Peritoneal dialysis (PD) was started. The mechanical ventilation was stopped at 1 month.
The infant was transferred to our hospital. Physical examination revealed a widened anterior fontanel and defects of temporal, occipital and parietal bones but no deformity of limbs. Serum creatinine was 1.98 mg/dL. Ultrasound examination revealed large kidneys with high echogenicity. The cranial computed tomography (CT) revealed hypoplasia of temporal, occipital and parietal bones ( Figure 1A) . At 2 months, some potion of urine passed and gradually increased to 80-160 mL/day. A renal biopsy was performed, revealing poor differentiation between proximal and distal convoluted tubules and increased intertubular mesenchyme ( Figure 1B ), indicative of RTD. Most tubules were small and collapsed. Some dilated tubules and tubular necrosis as well as dilated Bowman's capsules, lacking the glomerular tuft, were noted. At 5 months, she was discharged with dialysis. In a recent follow-up at 6 months, serum creatinine was 2.95 mg/dL. The cranial CT showed normal cranial bones. Her growth remains poor, at a weight 2,625 grams, but cognitive development is increasingly progressing. Table 1 summarizes the clinical characteristics of the reported infants with hypocalvaria and/or RTD after intrauterine exposure to agents that inhibit the renin-angiotensin system (RAS). Three infants after exposure to angiotensinconverting enzyme inhibitors [1] and four infants after exposure to ARBs [2] [3] [4] , includiing our patient (Case 7), were reported. Of four infants after exposure to ARBs, one developed hypocalvaria alone [3] . All infants with hypocalvaria and acute renal failure, except one case [4] , died or remained dependent on PD, suggesting a poor prognosis of these infants. Our patient showed growth of the calvarial bones as described [1, 4] , but remained dependent on PD because of RTD with dilated Bowman's capsules lacking the glomerular tuft. This glomerular change, characteristic of severe RTD, was found in three infants with poor outcome [1] . Our observation, together with previous cases, suggests that kidney damage, depending on the severity of RAS inhibition-induced hypotension and/or hypoxia during fetal life, is irreversible and a determinant of outcome, whereas hypocalvaria is reversible. 
